Bone Therapeutics Raises Series D
Bone Therapeutics, an international biopharmaceutical company focused on cell therapy products for the treatment of bone diseases has closed a Series D funding round, raising 7.7 million euros ($10.4 million) from current investors and the Walloon Region. Investors in the round included Nausicaa Ventures, BAMS Angels Fund I and Life Science Research Partners as well as the Société Régionale d'Investissement de Wallonie and Sambrinvest, two supportive Walloon Region controlled minority shareholders.
29 January 2013•2 mins read
